新冠疫苗接种与SARS-CoV-2阳性检测后血小板减少和血栓栓塞风险:自控病例系列研究
结果显示,ChAdOx1 nCoV-19和BNT162b2 mRNA疫苗接种后短时间内部分血液和血管事件风险增加,但SARS-CoV-2感染后多数事件风险更高且持续时间更长。
要点
- ChAdOx1 nCoV-19首剂后8-14天血小板减少风险增加(IRR 1.33,95%CI 1.19-1.47)。
- SARS-CoV-2阳性后8-14天静脉血栓栓塞风险显著增高(IRR 13.86,95%CI 12.76-15.05)。
- BNT162b2 mRNA首剂后15-21天动脉血栓栓塞风险轻度增加(IRR 1.06,95%CI 1.01-1.10)。
核心结论
- ChAdOx1 nCoV-19和BNT162b2 mRNA疫苗首剂后短时间内观察到导致住院或死亡的血液和血管事件风险增加。
- 在同一人群中,SARS-CoV-2感染后多数上述事件的风险显著高于且持续时间长于疫苗接种后。
研究设计与样本
- 研究对象为≥16岁接种ChAdOx1 nCoV-19或BNT162b2 mRNA疫苗首剂者及SARS-CoV-2检测阳性者,共纳入29 121 633名接种者(ChAdOx1 nCoV-19 19 608 008人,BNT162b2 mRNA 9 513 625人)和1 758 095名SARS-CoV-2阳性者。
主要发现
- ChAdOx1 nCoV-19接种后8-14天血小板减少风险增加(IRR 1.33,95%CI 1.19-1.47),SARS-CoV-2阳性后8-14天风险更高(IRR 5.27,95%CI 4.34-6.40)。
- ChAdOx1 nCoV-19接种后8-14天静脉血栓栓塞风险增加(IRR 1.10,95%CI 1.02-1.18),SARS-CoV-2阳性后8-14天风险显著增高(IRR 13.86,95%CI 12.76-15.05)。
- BNT162b2 mRNA接种后15-21天动脉血栓栓塞风险增加(IRR 1.06,95%CI 1.01-1.10),SARS-CoV-2阳性后15-21天风险更高(IRR 2.02,95%CI 1.82-2.24)。
- ChAdOx1 nCoV-19接种后8-14天脑静脉窦血栓形成风险增加(IRR 4.01,95%CI 2.08-7.71),BNT162b2 mRNA接种后15-21天风险亦增加(IRR 3.58,95%CI 1.39-9.27)。
- BNT162b2 mRNA接种后15-21天缺血性卒中风险增加(IRR 1.12,95%CI 1.04-1.20),ChAdOx1 nCoV-19接种后8-14天其他罕见动脉血栓事件风险增加(IRR 1.21,95%CI 1.02-1.43)。
关键数值与推荐
- 主要结局为三种暴露(ChAdOx1 nCoV-19首剂、BNT162b2 mRNA首剂、SARS-CoV-2阳性检测)后28天内与血小板减少、静脉血栓栓塞和动脉血栓栓塞相关的住院或死亡。
- 次要结局包括脑静脉窦血栓形成、缺血性卒中、心肌梗死和其他罕见动脉血栓事件。
临床怎么用
- 在全科诊疗中,对接种新冠疫苗后短期内出现血小板减少或血栓栓塞症状的患者应保持警惕并及时评估。
- 同时应认识到SARS-CoV-2感染后血栓栓塞风险更高且更持久,对感染者康复期进行血栓风险监测同样重要。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the association between covid-19 vaccines and risk of thrombocytopenia and thromboembolic events in England among adults. DESIGN: Self-controlled case series study using national data on covid-19 vaccination and hospital admissions. SETTING: Patient level data were obtained for approximately 30 million people vaccinated in England between 1 December 2020 and 24 April 2021. Electronic health records were linked with death data from the Office for National Statistics, SARS-CoV-2 positive test data, and hospital admission data from the United Kingdom's health service (NHS). PARTICIPANTS: 29 121 633 people were vaccinated with first doses (19 608 008 with Oxford-AstraZeneca (ChAdOx1 nCoV-19) and 9 513 625 with Pfizer-BioNTech (BNT162b2 mRNA)) and 1 758 095 people had a positive SARS-CoV-2 test. People aged ≥16 years who had first doses of the ChAdOx1 nCoV-19 or BNT162b2 mRNA vaccines and any outcome of interest were included in the study. MAIN OUTCOME MEASURES: The primary outcomes were hospital admission or death associated with thrombocytopenia, venous thromboembolism, and arterial thromboembolism within 28 days of three exposures: first dose of the ChAdOx1 nCoV-19 vaccine; first dose of the BNT162b2 mRNA vaccine; and a SARS-CoV-2 positive test. Secondary outcomes were subsets of the primary outcomes: cerebral venous sinus thrombosis (CVST), ischaemic stroke, myocardial infarction, and other rare arterial thrombotic events. RESULTS: The study found increased risk of thrombocytopenia after ChAdOx1 nCoV-19 vaccination (incidence rate ratio 1.33, 95% confidence interval 1.19 to 1.47 at 8-14 days) and after a positive SARS-CoV-2 test (5.27, 4.34 to 6.40 at 8-14 days); increased risk of venous thromboembolism after ChAdOx1 nCoV-19 vaccination (1.10, 1.02 to 1.18 at 8-14 days) and after SARS-CoV-2 infection (13.86, 12.76 to 15.05 at 8-14 days); and increased risk of arterial thromboembolism after BNT162b2 mRNA vaccination (1.06, 1.01 to 1.10 at 15-21 days) and after SARS-CoV-2 infection (2.02, 1.82 to 2.24 at 15-21 days). Secondary analyses found increased risk of CVST after ChAdOx1 nCoV-19 vaccination (4.01, 2.08 to 7.71 at 8-14 days), after BNT162b2 mRNA vaccination (3.58, 1.39 to 9.27 at 15-21 days), and after a positive SARS-CoV-2 test; increased risk of ischaemic stroke after BNT162b2 mRNA vaccination (1.12, 1.04 to 1.20 at 15-21 days) and after a positive SARS-CoV-2 test; and increased risk of other rare arterial thrombotic events after ChAdOx1 nCoV-19 vaccination (1.21, 1.02 to 1.43 at 8-14 days) and after a positive SARS-CoV-2 test. CONCLUSION: Increased risks of haematological and vascular events that led to hospital admission or death were observed for short time intervals after first doses of the ChAdOx1 nCoV-19 and BNT162b2 mRNA vaccines. The risks of most of these events were substantially higher and more prolonged after SARS-CoV-2 infection than after vaccination in the same population.
引用
- Hippisley-Cox J, Patone M, Mei XW, et al. Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study. BMJ. 2021. PMID: 34446426. doi:10.1136/bmj.n1931
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。